A promising, new experimental therapy for lung cancer will be presented at this year’s 16th World Conference on Lung Cancer, which will be held between the 6th and 9th of September in Denver and hosted by the International Association for the Study of Lung Cancer (IASLC). Clovis Oncology will present new data on Rociletinib at what is now the world’s largest international meeting dedicated to lung cancer and other thoracic malignancy researchers. This conference gathers researchers, medical specialists, nurses, patients, and advocates to discuss the latest developments in thoracic malignancy research.
Clovis Oncology, a biopharmaceutical company focused on developing and commercializing cancer treatments, will present a total of four mini-oral presentations and two posters on rociletinib (CO-1686). Rociletinib is an oral, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) under investigation for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). EGFR is a biological cell surface receptor of a set of proteins — members of the epidermal growth factors family that influences the expression of lung cancer.
Rociletinib is in Phase II of development for the treatment of non-small cell lung cancer and it targets the activating mutations of EGFR while it also suppresses the dominant acquired resistance mutation, T790M, which develops in 60 percent of patients treated with first- and second-generation EGFR inhibitors.
The following is the complete schedule of Clovis’ presentations:
Rociletinib in NSCLC patients with negative central testing for T790M in TIGER-X (Abstract #951/MINI03.10)
- Heather Wakelee, MD, Stanford University Medical Center
- Monday, Sept. 7, 4:45-6:15pm MT
- Location: Four Seasons Ballroom F1 + F2
Identification of effective drug combinations to prevent or delay resistance to the EGFR mutant selective inhibitor rociletinib (CO-1686) (Abstract #3010/MINI09.04)
- Andrew D. Simmons, PhD, Clovis Oncology
- Monday, Sept. 7, 4:45-6:15pm MT
- Location: Rooms 205 + 207
Dose optimization of rociletinib for EGFR mutated NSCLC (Abstract #967/MINI16.03)
- Jonathan W. Goldman, MD, UCLA Health
- Tuesday, Sept. 8, 4:45-6:15pm MT
- Location: Four Seasons Ballroom F3 + F4
Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement (Abstract #965/MINI16.04)
- D. Ross Camidge, MD, PhD, University of Colorado Denver
- Tuesday, Sept. 8, 4:45-6:15pm MT
- Location: Four Seasons Ballroom F3 + F4
Poster Sessions
Poster P1.01-076 – TIGER-1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer
- D. Ross Camidge, MD, PhD, University of Colorado Denver
- Monday, Sept. 7, 9:30am-4:45pm MT
- Location: Exhibit Hall
Poster P1.01-086 – TIGER-3: A phase 3, open-label, randomized study of rociletinib versus cytotoxic chemotherapy in patients with mutant EGFR non-small cell lung cancer progressing on prior EGFR tyrosine kinase inhibitor therapy and doublet chemotherapy
- James Chih-Hsin Yang, National Taiwan University Hospital
- Monday, Sept. 7, 9:30am-4:45pm MT
- Location: Exhibit Hall
In addition to Rociletinib, Clovis is also developing rucaparib, a compound in Phase II and III clinical trials for the treatment of ovarian cancer and lucitanib, and in Phase II trials for the treatment of breast and lung cancers. When asked about Clovis’ participation at this year’s lung cancer conference, Patrick J. Mahaffy, President and CEO of Clovis Oncology, noted his enthusiasm in sharing the updated data from Clovis’ last trials, adding that it was possible to analyze rociletinib’s activity in several subsets of patients with advanced EGFR mutation.